Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
Biography and Research Information
OverviewAI-generated summary
Takeo Shibata's research focuses on cancer immunotherapy, reproductive immunology, and obstetrics and gynecology. His work investigates the role of T cells in the regression of cervical high-grade squamous intraepithelial lesions following therapeutic vaccine administration. Shibata has also explored methods for DNA extraction from liquid-based cytology specimens to facilitate the study of cervical microbiota.
His publications include research on the effectiveness of prophylactic HPV vaccines against cervical abnormalities in Japan, a retrospective study on immunotherapy for cervical cancer using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS), and a randomized clinical trial evaluating treatments for cervical intraepithelial neoplasia. Additionally, Shibata has contributed to studies examining associations between maternal postpartum depression and psychosocial factors, and the potential of amniotic fluid as a delivery route for substances during fetal development.
Shibata has received several awards, including the UAMS Student Research Day Poster Presentations (2nd place post-doctoral category) in 2020, the Kanazawa Medical University support group Tachibanakai Award in 2016, and the Kanazawa Medical University President's Award in 2016. He has a h-index of 12, with 64 publications and 485 total citations. Key collaborators at the University of Arkansas for Medical Sciences include Mayumi Nakagawa and Hannah Coleman.
Metrics
- h-index: 12
- Publications: 64
- Citations: 493
Positions
-
Assistant Professor 2011–presentKanazawa Medical University Obstetrics and Gynecology ORCID
-
Assistant ProfessorUniversity of Arkansas for Medical Sciences ORCID
-
Postgraduate Clinical Resident 2009–2011Kanazawa Medical University Hospital Postgraduate Clinical Resident's Center ORCID
Selected Publications
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida (2025)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2021)
-
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2020)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2020)
-
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer (2019)
Collaboration Network
Top Collaborators
Mayumi Nakagawa
University of Arkansas for Medical Sciences
8 shared publications
In database
- The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
Showing 5 of 8 shared publications
Hannah Coleman
University of Arkansas for Medical Sciences
7 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Showing 5 of 7 shared publications
Benjamin J. Lieblong
University of Arkansas for Medical Sciences
5 shared publications
In database
- The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
Toshiyuki Sasagawa
Kanazawa Medical University (JP)
5 shared publications
- The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
William W. Greenfield
University of Arkansas for Medical Sciences
5 shared publications
In database
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Teresa Evans
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
Yong‐Chen Lu
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
Michael S. Robeson
University of Arkansas for Medical Sciences
4 shared publications
In database
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Sumit K. Shah
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
Charles M. Quick
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
Horace J. Spencer
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
Jasmine Crane
University of Arkansas for Medical Sciences
3 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Nadia Darwish
University of Arkansas for Medical Sciences
3 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Intawat Nookaew
University of Arkansas for Medical Sciences
3 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
David W. Ussery
University of Arkansas for Medical Sciences
3 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Similar Researchers
Based on overlapping research topics
William W. Greenfield
University of Arkansas for Medical Sciences
Cervical Cancer and HPV Research
Maternal and Perinatal Health Interventions
Immune Response and Inflammation
Brian Russ
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Maternal and Perinatal Health Interventions
Immune Response and Inflammation
Bhagyashri Bhende
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Microbial infections and disease research
Health Sciences Research and Education
Mugahed Hamza
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Cervical Cancer and HPV Research
Immune Response and Inflammation
Youssef Aachoui
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Microbial infections and disease research
Health Sciences Research and Education
Signe K. Larson
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Microbial infections and disease research
Health Sciences Research and Education